Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paul Fleming

Showing results (51-60 of 66) with videos related to

Pageof 7
Sort By:
Cancer Chemotherapy and Pharmacology|March 15, 2011
Preclinical evaluation of the antitumor activity of bortezomib in combination with vitamin C or with epigallocatechin gallate, a component of green teaBret Bannerman, Ling Xu, Matthew Jones, et al.
Access Microbiology|July 10, 2023
Trends in coagulase-negative staphylococci (CoNS), England, 2010-2021Karthik Paranthaman, Allegra Wilson, Neville Verlander, et al.
Antiviral Research|April 10, 2016
Novel diversity-oriented synthesis-derived respiratory syncytial virus inhibitors identified via a high throughput replicon-based screenJeremy R Duvall, Lynn VerPlank, Barbara Ludeke, et al.
Archives of Disease in Childhood. Fetal and Neonatal Edition|September 26, 2023
Clinical outcomes of <i>Staphylococcus capitis</i> isolation from neonates, England, 2015-2021: a retrospective case-control studyJin-Min Yuan, Christopher Nugent, Allegra Wilson, et al.
Bioorganic & Medicinal Chemistry Letters|September 30, 2010
Optimization of a series of dipeptides with a P3 threonine residue as non-covalent inhibitors of the chymotrypsin-like activity of the human 20S proteasomeChristopher Blackburn, Cynthia Barrett, Jonathan L Blank, et al.
Cancer Research|February 18, 2010
Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancerErik Kupperman, Edmund C Lee, Yueying Cao, et al.
The Biochemical Journal|July 17, 2010
Characterization of a new series of non-covalent proteasome inhibitors with exquisite potency and selectivity for the 20S beta5-subunitChristopher Blackburn, Kenneth M Gigstad, Paul Hales, et al.
International Journal of Cancer|January 12, 2026
Outcomes from the English National Lynch Syndrome transformation projectKevin J Monahan, Paul Fleming, Neil A J Ryan, et al.
BMC Pediatrics|July 18, 2024
Whole-body hypothermia in mild neonatal encephalopathy: protocol for a multicentre phase III randomised controlled trialReema Garegrat, Paolo Montaldo, Constance Burgod, et al.
ACS Chemical Biology|July 19, 2014
Pyrazolopyrimidines establish MurC as a vulnerable target in Pseudomonas aeruginosa and Escherichia coliShahul Hameed P, Praveena Manjrekar, Murugan Chinnapattu, et al.
Pageof 7

Showing results (51-60 of 66) with videos related to

Sort By:
Pageof 7
Cancer Chemotherapy and Pharmacology|March 15, 2011
Preclinical evaluation of the antitumor activity of bortezomib in combination with vitamin C or with epigallocatechin gallate, a component of green teaBret Bannerman, Ling Xu, Matthew Jones, et al.
Access Microbiology|July 10, 2023
Trends in coagulase-negative staphylococci (CoNS), England, 2010-2021Karthik Paranthaman, Allegra Wilson, Neville Verlander, et al.
Antiviral Research|April 10, 2016
Novel diversity-oriented synthesis-derived respiratory syncytial virus inhibitors identified via a high throughput replicon-based screenJeremy R Duvall, Lynn VerPlank, Barbara Ludeke, et al.
Archives of Disease in Childhood. Fetal and Neonatal Edition|September 26, 2023
Clinical outcomes of <i>Staphylococcus capitis</i> isolation from neonates, England, 2015-2021: a retrospective case-control studyJin-Min Yuan, Christopher Nugent, Allegra Wilson, et al.
Bioorganic & Medicinal Chemistry Letters|September 30, 2010
Optimization of a series of dipeptides with a P3 threonine residue as non-covalent inhibitors of the chymotrypsin-like activity of the human 20S proteasomeChristopher Blackburn, Cynthia Barrett, Jonathan L Blank, et al.
Cancer Research|February 18, 2010
Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancerErik Kupperman, Edmund C Lee, Yueying Cao, et al.
The Biochemical Journal|July 17, 2010
Characterization of a new series of non-covalent proteasome inhibitors with exquisite potency and selectivity for the 20S beta5-subunitChristopher Blackburn, Kenneth M Gigstad, Paul Hales, et al.
International Journal of Cancer|January 12, 2026
Outcomes from the English National Lynch Syndrome transformation projectKevin J Monahan, Paul Fleming, Neil A J Ryan, et al.
BMC Pediatrics|July 18, 2024
Whole-body hypothermia in mild neonatal encephalopathy: protocol for a multicentre phase III randomised controlled trialReema Garegrat, Paolo Montaldo, Constance Burgod, et al.
ACS Chemical Biology|July 19, 2014
Pyrazolopyrimidines establish MurC as a vulnerable target in Pseudomonas aeruginosa and Escherichia coliShahul Hameed P, Praveena Manjrekar, Murugan Chinnapattu, et al.
Pageof 7